Rysz-Górzyńska Magdalena, Banach Maciej
Department of Nephrology, Hypertension and Family Medicine, Healthy Aging Research Center, Medical University of Lodz, Lodz, Poland.
Department of Hypertension, Medical University of Lodz, Lodz, Poland.
Arch Med Sci. 2016 Aug 1;12(4):844-9. doi: 10.5114/aoms.2016.60971. Epub 2016 Jul 1.
A number of studies have shown that chronic kidney disease (CKD) is associated with increased risk for cardiovascular disease (CVD). Chronic kidney disease is characterized by significant disturbances in lipoprotein metabolism, including differences in quantitative and qualitative content of high-density lipoprotein (HDL) particles. Recent studies have revealed that serum HDL cholesterol levels do not predict CVD in CKD patients; thus CKD-induced modifications in high-density lipoprotein (HDL) may be responsible for the increase in CV risk in CKD patients. Various methods are available to separate several subclasses of HDL and confirm their atheroprotective properties. However, under pathological conditions associated with inflammation and oxidation, HDL can progressively lose normal biological activities and be converted into dysfunctional HDL. In this review, we highlight the current state of knowledge on subfractions of HDL and HDL dysfunction in CKD.
多项研究表明,慢性肾脏病(CKD)与心血管疾病(CVD)风险增加相关。慢性肾脏病的特征是脂蛋白代谢存在显著紊乱,包括高密度脂蛋白(HDL)颗粒在数量和质量上的差异。近期研究显示,血清HDL胆固醇水平并不能预测CKD患者的CVD;因此,CKD引起的高密度脂蛋白(HDL)改变可能是CKD患者心血管风险增加的原因。有多种方法可用于分离HDL的几个亚类并证实其抗动脉粥样硬化特性。然而,在与炎症和氧化相关的病理条件下,HDL会逐渐丧失正常生物学活性并转化为功能失调的HDL。在本综述中,我们重点介绍了目前关于CKD中HDL亚组分和HDL功能障碍的知识现状。